Circulating Cell-Free DNA Profiling Predicts the Therapeutic Outcome in Advanced Hepatocellular Carcinoma Patients Treated with Combination Immunotherapy

SIMPLE SUMMARY: Atezolizumab/bevacizumab (Atezo/Bev) combination immunotherapy has become a front-line therapy for unresectable hepatocellular carcinoma (u-HCC), but some patients are initially nonresponders. We investigated the potential of cell-free DNA (cfDNA)/circulating tumor DNA (ctDNA) as bio...

Descripción completa

Detalles Bibliográficos
Autores principales: Matsumae, Takayuki, Kodama, Takahiro, Myojin, Yuta, Maesaka, Kazuki, Sakamori, Ryotaro, Takuwa, Ayako, Oku, Keiko, Motooka, Daisuke, Sawai, Yoshiyuki, Oshita, Masahide, Nakabori, Tasuku, Ohkawa, Kazuyoshi, Miyazaki, Masanori, Tanaka, Satoshi, Mita, Eiji, Tawara, Seiichi, Yakushijin, Takayuki, Nozaki, Yasutoshi, Hagiwara, Hideki, Tahata, Yuki, Yamada, Ryoko, Hikita, Hayato, Tatsumi, Tomohide, Takehara, Tetsuo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9320668/
https://www.ncbi.nlm.nih.gov/pubmed/35884434
http://dx.doi.org/10.3390/cancers14143367

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9320668/
https://www.ncbi.nlm.nih.gov/pubmed/35884434
http://dx.doi.org/10.3390/cancers14143367

Ejemplares similares